There are currently 487 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Autism participants are California, Ohio, Illinois and Michigan.
Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery
NCT04233385
Recruiting
About 25-50% of women who undergo breast cancer surgery develop persistent chest wall pain and shoulder mobility limitations following surgery. The pain and mobility limitations adversely affect quality of life, sleep, and body image. Unfortunately, current treatments for pain and mobility limitations have variable efficacy. Based on a review of relevant pre-, intra-, and post-operative factors, investigators reasoned that myofascial massage may address contributors to pain and mobility limitati... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/28/2023
Locations: MetroHealth Medical Center, Cleveland, Ohio
Conditions: Breast Cancer, Mastectomy; Lymphedema, Pain, Shoulder, Mobility Limitation
Register for Updates
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
NCT05587972
Recruiting
The Carevive registry collects patient characteristics, patient symptoms, and treatment experience data from patients receiving cancer treatment for breast, lung, GI or multiple myeloma. For this study, a core set of variables is collected on each patient in the Carevive platform. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic Patient Reported Outcome surveys are collected fr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Multiple Myeloma
Register for Updates
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT04906395
Recruiting
This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The study will also aim to assess the safety of TOL2506 in men with HR+, HER2-negative breast cancer. The Screening Period will be conducted in two parts: 1) an abbreviated, initial screening where premenopausal status will be determined prior to neoadjuvant or adjuvant chemotherapy (if planned) and 2) the full screenin... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
05/03/2024
Locations: Arizona Oncology Associates, PC, Glendale, Arizona +54 locations
Conditions: Breast Cancer
Register for Updates
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
NCT05573555
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer. This study is seeking participants who have breast cancer that: is advanced, may have spread to other organs (metastatic) and cannot be fully treated by surgery or radiation therapy is sensitive to hormonal therapy (it is called estrogen receptor positive); and is no longe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/03/2024
Locations: Stanford Women's Cancer Center, Palo Alto, California +43 locations
Conditions: Breast Cancer
Register for Updates
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
NCT05963997
Recruiting
This is an international, multisite, open-label, Phase 1b/2 study, to confirm safety and efficacy of samuraciclib in combination with elacestrant in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/03/2024
Locations: Site 43 - Mid Florida Hematology and Oncology Center, Orange City, Florida +26 locations
Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Register for Updates
Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening
NCT04877912
Recruiting
The purpose of this study is to test an innovative MRI breast cancer screening method in women with mammographically dense breasts as well as other women with moderately increased cancer risk. MRI, combined with other methods of risk assessment, has potential to significantly improve sensitivity to cancer in dense breasts and detect cancer in all cases at a much earlier stage, with far fewer interval cancers than mammography. Previous tests of MRI sensitivity show that this screening could signi... Read More
Gender:
Female
Ages:
Between 40 years and 74 years
Trial Updated:
05/03/2024
Locations: University of Chicago Mitchell Hospital, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates
Genomic Services Research Program
NCT02595957
Recruiting
Background: Genes are the instructions a person s body uses to function. Genome sequencing is a new way to look at genes that your main research team is using to learn the causes of the condition they are studying. When a new cause is found this way, it is called a primary variant. Each person has many variants. Most do not cause disease. Sequencing can also find secondary variants. These are not related to the condition your main research team is studying, but may show a person to be at high r... Read More
Gender:
All
Ages:
Between 1 month and 105 years
Trial Updated:
05/02/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Colon Cancer, Breast Cancer
Register for Updates
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05232916
Recruiting
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third op... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/02/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +143 locations
Conditions: Breast Cancer
Register for Updates
Breast Cancer, Reasoning, and Activity Intervention
NCT04816006
Recruiting
This phase II trial tests whether an exercise intervention works to improve cognitive function in breast cancer survivors. Many breast cancer survivors report cancer-related cognitive impairment, which this has recently become a priority in clinical research due to its dramatic impact on daily functioning, quality of life, and long-term health. Aerobic exercise has the potential to improve cognitive function and brain health in older adults and is recommended as a safe, tolerable, and accessible... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Breast Cancer, Breast Neoplasms, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Cancer-related Cognitive Dysfunction
Register for Updates
Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: SystImmune Recruiting Site, Orange, California +9 locations
Conditions: Non Small Cell Lung Cancer, NSCLC, Lung Cancer, Breast Cancer, Esophageal Cancer, SCLC, Small Cell Lung Cancer, NPC, Nasopharyngeal Cancer
Register for Updates
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
NCT06253520
Recruiting
Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. One approach to treating these cancers is to take disease-fighting white blood cells from a person, change those cells so they will target the specific proteins (called antigens) from the cancer cells, and return them to that person s blood. The use of the white blood cells in this manner is one form of gene therapy. A vaccine may help these modi... Read More
Gender:
All
Ages:
Between 18 years and 72 years
Trial Updated:
05/02/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Gastrointestinal Cancer, Ovarian Cancer, Genitourinary Cancer
Register for Updates
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT03412877
Recruiting
Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs in a laboratory. A type of virus is used to transfer the genes that make those white blood cells able to attack the mutation in the tumor. The gene transfer therapy is the return of those white blood... Read More
Gender:
All
Ages:
Between 18 years and 72 years
Trial Updated:
05/02/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Endocrine Tumors, Neuroendocrine Tumors, Gastrointestinal/Genitourinary Cancers, Multiple Myeloma
Register for Updates